Screener
Amneal Pharmaceuticals, Inc. AMRX AvKARE — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
| Operating income (loss) | $123,078 | $54,856 | $9,336 | $(57,501) | $129,769 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss)?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — operating income (loss) of $9.34M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss) changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss) decreased by 48.6% year-over-year, from $18.15M to $9.34M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss)?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss) has grown at a 87.3% compound annual growth rate (CAGR), from $6.8M to $83.62M.
- What does avkare — operating income (loss) mean?
- Measures the core profitability of the business segment by subtracting operating expenses from gross profit. It serves as a primary indicator of the segment's operational efficiency and ability to generate earnings from its specific product portfolio.
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude